Today's story
Roche beats sales forecasts, reaffirms outlook
Roche Q3 sales reached 16.13 billion Swiss francs, beating the roughly 15.8 billion franc analyst estimate, and the company reaffirmed its 2026 outlook.
Business · 8 sources · Oct 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About omalizumab
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.
Everything about omalizumab →